Form 4: Cogent Biosciences Director Receives Equity Compensation

Cogent Biosciences director Karen Jean Ferrante was granted 643 stock options as part of her compensation, aligning her interests with shareholders.

Summary

• Karen Jean Ferrante, a Director at Cogent Biosciences, Inc. (COGT), reported an acquisition of derivative securities.
• On January 1, 2026, Ferrante acquired 643 stock options.
• These options have an exercise price of $34.74 per share.
• The options become exercisable on January 1, 2026, and are set to expire on January 1, 2036.
• The option award was issued to Ferrante, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan.
• The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.
• Following this transaction, Ferrante beneficially owns 643 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of director compensation in the form of stock options, which is a neutral event in itself. The choice of equity over cash can be seen as a minor positive for alignment of interests.

Positives

• Director Karen Jean Ferrante elected to receive equity compensation (stock options) instead of cash, which aligns her interests with those of shareholders.
• The grant is part of a structured non-employee director compensation plan, indicating a formal governance framework for executive compensation.

Future Outlook

NA

Industry Context

This is a routine insider transaction disclosure, common across all industries for publicly traded companies, reflecting a director's compensation choice. It does not provide broader industry trends or competitive insights.

Corporate Governance

Related Party Transactions

• The grant of 643 stock options to Director Karen Jean Ferrante constitutes a related party transaction as part of her compensation under the non-employee director compensation plan.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns her interests with shareholders, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on employees is mentioned in this filing.

Key Dates

Keywords

Cogent Biosciences, COGT, Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Compensation, Karen Jean Ferrante, SEC Filing